Keller Cecconello Daiane, Spagnol Fabiane, Alegretti Ana Paula, Pilger Diogo André, Farias Mariela Granero
Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Hematol Transfus Cell Ther. 2024 Nov;46 Suppl 5(Suppl 5):S136-S142. doi: 10.1016/j.htct.2023.07.002. Epub 2023 Aug 28.
Flow Cytometry (FC) is one of the techniques, which allows the identification and characterization of platelets. The detection of absent or reduced expression of the glycoproteins is the main objective of this technique. Abnormalities of glycoproteins lead to hemorrhagic syndromes. Among the main diseases, the Bernard-Soulier syndrome (BSS) and Glanzmann thrombasthenia (GT) stand out. We aimed to show a FC-based platelet assessment test for diagnostic use, which measures the expression of markers in normal patients, and evaluate these markers in patients with platelet disorders.
We examined a control group of 41 healthy adults to establish reference values and assess the variability of the relative expression of platelet markers and subsequently compared these findings to those of 30 patients with suspected platelet dysfunctions. We determined the mean fluorescent intensity (MFI) of the expressed parameters by FC using CD41, CD42a, CD42b and CD61 and SSC/FSC platelet-gated cells.
We determined our baseline panel of markers and compared them to suspected platelet dysfunctions. Patients with suspected BSS presented increased levels of the MFI for the GPIIIa (CD61) and GPIIb (CD41). They showed significantly reduced levels of the GPIb (CD42b) and GPIX (CD42a). Patients with suspected GT showed normal expression of the GPIX (CD42a), increased expression of the GPIb (CD42b) and reduced levels of the GPIIIa (CD61). In this case, with reduced levels of only one marker, the GPIIb (CD41), values showed normal expression.
We describe the FC assay to support the diagnosis of different platelet disorders. Our study made it possible to implement a technique that brought benefits to care.
流式细胞术(FC)是一种可用于鉴定和表征血小板的技术。检测糖蛋白表达缺失或降低是该技术的主要目的。糖蛋白异常会导致出血综合征。在主要疾病中,伯纳德-索利尔综合征(BSS)和血小板无力症(GT)较为突出。我们旨在展示一种基于流式细胞术的血小板评估测试,用于诊断,该测试可测量正常患者中标志物的表达,并评估血小板疾病患者的这些标志物。
我们检查了41名健康成年人的对照组,以建立参考值并评估血小板标志物相对表达的变异性,随后将这些结果与30名疑似血小板功能障碍患者的结果进行比较。我们使用CD41、CD42a、CD42b和CD61以及SSC/FSC血小板门控细胞,通过流式细胞术确定表达参数的平均荧光强度(MFI)。
我们确定了标志物的基线面板,并将其与疑似血小板功能障碍进行比较。疑似BSS的患者,其糖蛋白IIIa(CD61)和糖蛋白IIb(CD41)的MFI水平升高。他们的糖蛋白Ib(CD42b)和糖蛋白IX(CD42a)水平显著降低。疑似GT的患者,糖蛋白IX(CD42a)表达正常,糖蛋白Ib(CD42b)表达增加,糖蛋白IIIa(CD61)水平降低。在这种情况下,仅一种标志物糖蛋白IIb(CD41)水平降低,其他值显示表达正常。
我们描述了用于支持诊断不同血小板疾病的流式细胞术检测方法。我们的研究使得实施一种对医疗护理有益的技术成为可能。